Immunocore is a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases.
About us
Our vision at Immunocore is to continue to deliver transformational science that transforms lives.
Our technology
Our foundation is built on our proprietary soluble TCR bi-specific ImmTAC® platform.
Pipeline
We have a robust pipeline of wholly owned and partnered programmes to address a broad spectrum of disease indications.
Latest news
3 June 2019
New Biomarker Research Builds Further Understanding of Tebentafusp (IMCgp100) Mechanism of Action, Link to Clinical Activity in Advanced Melanoma
30 May 2019
Immunocore to present at the Jefferies 2019 Global Healthcare Conference in New York
16 May 2019
Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting
13 May 2019
Immunocore Launches Campaign to Educate Physicians on Rare Eye Cancer